biOasis Technologies Ord Shs BIOAF

Primary Symbol: V.BTI.H

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > FDA Approval of PRX-102 (Elfabrio)

<< Previous

Bullboard Posts

Next >>

Comment by Boomskidon May 11, 2023 3:25pm

113 Views

Post# 35443885

RE:RE:FDA Approval of PRX-102 (Elfabrio)

Zwerp says BTI didn't move on the FDA approval of PRX-102.

Although that's something less than an astute observation, it's also a ridiculous expectation. The approval may trigger other events, and those events, as described, could create something interesting for Bioasis. But that's a lot of buts and ifs.

It gets really weird and stupid here at times.

jd

<< Previous

Bullboard Posts

Next >>

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload